Kurian Abraham, MD, is a Diplomate of ABPN (American Board of Psychiatry and Neurology). Dr. Abraham obtained his medical Degree and pulmonology fellowship from KEM Hospital Bombay, Psychiatry residency from EVMS Norfolk, Virginia and Fellowship in Neuro-Psychopharmacology and New drug development from Duke University (Duke/Glaxo-Smith Kline Fellow). Dr. Abraham is the Medical Director of New Hope Clinical Research at 3101 Latrobe Drive, Charlotte 28211 and trains all the investigators of New Hope Clinical Research. Dr.Abraham has extensive experience in all phases of Clinical trials from Phase I-IV. Dr. Abraham has been involved with at least 100+ protocols as Independent Principal Investigator and another 100+ protocols as Sub-Investigator while at Duke as a fellow.
Jonathan Davidson M.D. was Dr. Abraham’s preceptor at Duke. Andrew Johnston PharmD, Alan Metz M.D., Robert Leadbetter M.D., and Jack Modell M.D. were the preceptors at GSK.
As a Duke/GSK fellow Dr. Abraham relentlessly worked hard at the Anxiety and Trauma Division at Duke under Dr. Davidson to validate CAPS (Clinician Administered PTSD Scale) and DTS (Davidson’s Trauma Scale). As a fellow at GSK Dr. Abraham’s project was anticonvulsant Lamotrigine (Lamictal) as a mood stabilizer and prophylaxis for the prevention of Manic Episodes in Bipolar Disorder and FDA approved Lamotrigine for that indication.
Dr. Abraham has won awards for most outstanding resident for Research during his residency and has few publications to his credit.